Donidalorsen Treatment in Children With Hereditary Angioedema
Part of paid clinical trials in Santa Monica, California.
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Study ID
- NCT07298447
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Hereditary Angioedema (HAE)
Eligibility Criteria
- Sex
- ALL
- Age
- 2 Years - 11 Years
- Healthy Volunteers
- Not accepted
Interventions
- Donidalorsen — DRUGDonidalorsen will be administered by subcutaneous (SC) injection.
Study Details
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of donidalorsen in pediatric participants with hereditary angioedema (HAE) Type I (HAE-1) or Type II (HAE-2).
Key Dates
- Start date
- Apr 21, 2026
- Status verified
- May 2026
- Primary completion
- Jun 30, 2029
- Completion
- Jun 30, 2029
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Donidalorsen: Group 1Participant weighing 9 kilograms (kg) to less than (\<)26 kg, will be administered donidalorsen over the period of one year.
- Experimental: Donidalorsen: Group 2Participant weighing greater than or equal to (≥)26 kg to \<41 kg, will be administered donidalorsen over the period of one year.
- Experimental: Donidalorsen: Group 3Participant weighing ≥41kg, will receive donidalorsen over the period of one year.
Primary Outcome Measure
Number of Participants with Treatment Emergent Adverse Events (TEAEs) [ Time Frame: over the period of approximately 17 months ]
Central Contacts
- Ionis Pharmaceuticals, Inc.(844) 201-3192
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Ionis Investigative Site | Santa Monica | California | 90404 | - |
| Ionis Investigative Site | Miami | Florida | 33136 | - |
| Ionis Investigative Site | St Louis | Missouri | 63141 | - |
| Ionis Investigative Site | Cincinnati | Ohio | 45236 | - |
| Ionis Investigative Site | Hershey | Pennsylvania | 17033 | - |
Find similar trials in Santa Monica, CA
Related Studies
- Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary AngioedemaPHASE2/PHASE3 · Enrolling By Invitation · Pharvaris Netherlands B.V. · Birmingham, Alabama
- Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEPHASE3 · Recruiting · Pharvaris Netherlands B.V. · Birmingham, Alabama
- A Study of Navenibart in Participants With Hereditary AngioedemaPHASE3 · Enrolling By Invitation · Astria Therapeutics, Inc. · Birmingham, Alabama
- A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaPHASE3 · Enrolling By Invitation · Astria Therapeutics, Inc. · Scottsdale, Arizona